Showing results (71-80 of 159) with videos related to
Sort By:
Pageof 16
Seminars in Cutaneous Medicine and Surgery|April 4, 2018
Treating to Target-A Realistic Goal in Psoriasis?Kenneth B Gordon, April W Armstrong, M Alan Menter, et al.Advances in Therapy|March 22, 2022
Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe PsoriasisCraig L Leonardi, Kyoungah See, Russel Burge, et al.American Journal of Clinical Dermatology|January 31, 2018
Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or PsoriasisCaitriona Ryan, Jeffrey M Sobell, Craig L Leonardi, et al.The New England Journal of Medicine|November 25, 2003
Etanercept as monotherapy in patients with psoriasisCraig L Leonardi, Jerold L Powers, Robert T Matheson, et al.The New England Journal of Medicine|June 15, 2016
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque PsoriasisKenneth B Gordon, Andrew Blauvelt, Kim A Papp, et al.Annals of the Rheumatic Diseases|May 8, 2012
Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's diseaseGerd R Burmester, Remo Panaccione, Kenneth B Gordon, et al.Blood|May 3, 2002
Differential abilities of central nervous system resident endothelial cells and astrocytes to serve as inducible antigen-presenting cellsAnn M Girvin, Kenneth B Gordon, C Jane Welsh, et al.Journal of the American Academy of Dermatology|October 22, 2011
Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasisDavid M Pariser, Craig L Leonardi, Kenneth Gordon, et al.Archives of Dermatology|February 20, 2008
Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trialAlexa B Kimball, Kenneth B Gordon, Richard G Langley, et al.Journal of the American Academy of Dermatology|December 15, 2010
Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trialAlexa B Kimball, Kenneth B Gordon, Richard G Langley, et al.Pageof 16